MDT-AP-0499
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 72
- os_event
- false
- age_years
- 8
- sex
- F
- new_clusters
- C3
- umap1_2d
- 4.469852709
- umap2_2d
- 2.64229301
- umap1_3d
- 1.599836295
- umap2_3d
- -1.391236663
- umap3_3d
- -1.100206853
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.440
- INFLAMMATORY_RESPONSE+0.410
- IL6_JAK_STAT3_SIGNALING+0.400
- COAGULATION+0.390
- INTERFERON_GAMMA_RESPONSE+0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.380
- COMPLEMENT+0.370
- TNFA_SIGNALING_VIA_NFKB+0.360
- OXIDATIVE_PHOSPHORYLATION+0.350
- INTERFERON_ALPHA_RESPONSE+0.340
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.450
- MITOTIC_SPINDLE-0.390
- G2M_CHECKPOINT-0.370
- MYC_TARGETS_V2-0.350
- WNT_BETA_CATENIN_SIGNALING-0.350
- E2F_TARGETS-0.320
- UNFOLDED_PROTEIN_RESPONSE-0.240
- PROTEIN_SECRETION-0.150
- PI3K_AKT_MTOR_SIGNALING-0.140
- CHOLESTEROL_HOMEOSTASIS-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-50-5045-01A-01R-1628-07 | — | cohortA1 | 0.893 |
| 2 | AUR-AFUL-TTP1-A-1-1-R-A743-41 | — | C | 0.892 |
| 3 | MDT-AP-0410 | Med | Medulloblastoma | 0.875 |
| 4 | SJEPD013_D.RNA-Seq | EPN | Posterior Fossa EPN | 0.873 |
| 5 | MDT-AP-2405 | Med | Medulloblastoma | 0.867 |
| 6 | SRR5088906 | — | — | 0.865 |
| 7 | SRR1410956 | GTEX | — | 0.864 |
| 8 | TCGA-64-1676-01A-01R-0946-07 | — | cohortA1 | 0.863 |
| 9 | TCGA-34-5234-01A-01R-1635-07 | — | cohortSQ1 | 0.862 |
| 10 | ad2bbb19-6d02-480f-b011-d4327c3c5607 | — | — | 0.861 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.440 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.410 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.400 | Inavolisib | — uncovered |
| COAGULATION | 0.390 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.390 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.380 | Inavolisib | — uncovered |
| COMPLEMENT | 0.370 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.360 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.350 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.340 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.340 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.330 | Remibrutinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.300 | Idelalisib | — uncovered |
| TGF_BETA_SIGNALING | 0.270 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.260 | Inavolisib | — uncovered |
| APOPTOSIS | 0.250 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.250 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.230 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| ADIPOGENESIS | 0.210 | Inavolisib | — uncovered |